Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-04-08 Sale |
2024-04-09 4:25 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $54.17 | $3,743,605 | 1,153,263 (Direct) |
View |
| 2024-04-01 Sale |
2024-04-02 4:06 pm |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
4,000 | $58.66 | $234,640 | 407,473 (Indirect Direct) |
View |
| 2024-03-19 Sale |
2024-03-20 5:18 pm |
Apellis Pharmaceuticals Inc. | APLS | Dunlop A. Sinclair Director |
18,681 | $57.18 | $1,068,161 | 337,871 (Indirect Direct) |
View |
| 2024-03-18 Sale |
2024-03-19 4:03 pm |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
9,913 | $56.9 | $564,050 | 54,693 (Direct) |
View |
| 2024-03-15 Sale |
2024-03-18 4:19 pm |
Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer |
184 | $56.46 | $10,389 | 38,883 (Direct) |
View |
| 2024-03-13 Sale |
2024-03-14 4:17 pm |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
11,220 | $57.56 | $645,838 | 56,287 (Direct) |
View |
| 2024-03-08 Sale |
2024-03-11 4:08 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $62.19 | $4,297,549 | 1,222,370 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:07 pm |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
250,000 | $64.11 | $16,028,706 | 2,219,608 (Indirect Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 4:04 pm |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
6,000 | $63.22 | $379,340 | 411,473 (Indirect Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 5:06 pm |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
781 | $67.77 | $52,926 | 194,095 (Indirect Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 5:05 pm |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
1,148 | $67.77 | $77,796 | 92,453 (Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 4:59 pm |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
1,431 | $67.77 | $96,974 | 149,570 (Indirect Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 4:49 pm |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
3,962 | $67.77 | $268,492 | 2,035,230 (Indirect Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 4:43 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
1,148 | $67.77 | $77,796 | 1,115,983 (Direct) |
View |
| 2024-02-12 Sale |
2024-02-13 4:38 pm |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
597 | $67.77 | $40,457 | 64,606 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:38 pm |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
906 | $64.14 | $58,109 | 194,876 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:36 pm |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
906 | $64.14 | $58,109 | 93,601 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:34 pm |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
906 | $64.14 | $58,109 | 151,001 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:31 pm |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
835 | $64.14 | $53,555 | 67,507 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:28 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
1,250 | $65.12 | $81,402 | 46,387 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:26 pm |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
2,843 | $64.14 | $182,345 | 2,039,192 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:23 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
1,250 | $65.22 | $81,524 | 57,208 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:21 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
874 | $64.14 | $56,057 | 1,117,131 (Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 4:18 pm |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
367 | $64.14 | $23,539 | 65,203 (Direct) |
View |
| 2024-01-23 Sale |
2024-01-24 4:06 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
4,286 | $63.69 | $272,975 | 47,637 (Direct) |
View |
| 2024-01-23 Sale |
2024-01-24 4:03 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
7,378 | $63.69 | $469,905 | 58,458 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 7:28 pm |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
13,431 | $65 | $872,961 | 2,042,035 (Indirect Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:17 pm |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
4,184 | $65 | $271,943 | 195,782 (Indirect Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:15 pm |
Apellis Pharmaceuticals Inc. | APLS | Townsend Adam J. Chief Commercial Officer |
3,413 | $65 | $221,831 | 94,507 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:13 pm |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
3,551 | $65 | $230,801 | 151,907 (Indirect Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:11 pm |
Apellis Pharmaceuticals Inc. | APLS | Nicholson Nur Chief Technical Officer |
2,593 | $65 | $168,535 | 68,342 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:07 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
1,738 | $65 | $112,963 | 51,923 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:05 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
1,607 | $65 | $104,449 | 65,836 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:03 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
3,913 | $65 | $254,329 | 1,118,005 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:01 pm |
Apellis Pharmaceuticals Inc. | APLS | DeLong Mark Jeffrey Chief Business & Strat Officer |
1,384 | $65 | $89,954 | 65,570 (Direct) |
View |
| 2024-01-22 Sale |
2024-01-23 6:00 pm |
Apellis Pharmaceuticals Inc. | APLS | Chopas James George VP/Chief Accounting Officer |
1,061 | $65 | $68,961 | 39,067 (Direct) |
View |
| 2024-01-17 Sale |
2024-01-18 4:55 pm |
Apellis Pharmaceuticals Inc. | APLS | Eisele Jeffrey Chief Development Officer |
5,207 | $65.58 | $341,475 | 67,443 (Direct) |
View |
| 2024-01-17 Sale |
2024-01-18 4:54 pm |
Apellis Pharmaceuticals Inc. | APLS | Lewis Karen Chief People Officer |
3,276 | $65.58 | $214,840 | 53,661 (Direct) |
View |
| 2024-01-16 Sale |
2024-01-17 4:47 pm |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
1,632 | $66.81 | $109,032 | 1,131,723 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-04-08 Exercise |
2024-04-09 4:25 pm |
N/A 2026-02-07 |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $0 | 1,153,263 (Direct) |
View |
| 2024-04-08 Exercise |
2024-04-09 4:25 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $3.76 | 1,153,263 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-02 4:06 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
4,000 | $10.03 | 407,473 (Direct) |
View |
| 2024-04-01 Exercise |
2024-04-02 4:06 pm |
N/A 2027-10-18 |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
4,000 | $0 | 407,473 (Direct) |
View |
| 2024-03-08 Exercise |
2024-03-11 4:08 pm |
N/A 2026-02-07 |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $0 | 1,222,370 (Direct) |
View |
| 2024-03-08 Exercise |
2024-03-11 4:08 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
69,107 | $3.67 | 1,222,370 (Direct) |
View |
| 2024-03-06 Exercise |
2024-03-08 07:45 am |
N/A 2029-02-07 |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
3,762 | $0 | 197,857 (Direct) |
View |
| 2024-03-06 Exercise |
2024-03-08 07:45 am |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Watson David O. General Counsel |
3,762 | $13.85 | 197,857 (Direct) |
View |
| 2024-03-01 Exercise |
2024-03-05 4:07 pm |
N/A 2026-02-06 |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
250,000 | $0 | 2,219,608 (Direct) |
View |
| 2024-03-01 Exercise |
2024-03-05 4:07 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
200,000 | $4.31 | 2,219,608 (Direct) |
View |
| 2024-03-01 Exercise |
2024-03-05 4:07 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Francois Cedric Chief Executive Officer |
50,000 | $3.76 | 2,219,608 (Direct) |
View |
| 2024-03-01 Exercise |
2024-03-05 4:04 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
6,000 | $10.03 | 411,473 (Direct) |
View |
| 2024-03-01 Exercise |
2024-03-05 4:04 pm |
N/A 2027-10-18 |
Apellis Pharmaceuticals Inc. | APLS | Sullivan Timothy Eugene Chief Financial Officer |
6,000 | $0 | 411,473 (Direct) |
View |
| 2024-01-16 Option Award |
2024-01-17 4:47 pm |
N/A N/A |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
6,743 | $0 | 1,131,723 (Direct) |
View |
| 2024-01-16 Option Award |
2024-01-17 4:47 pm |
N/A 2034-01-15 |
Apellis Pharmaceuticals Inc. | APLS | Deschatelets Pascal Chief Scientific Officer |
9,805 | $66.3 | 1,131,723 (Direct) |
View |